Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 16/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2255345 | 1.00 | SSTR4 (0.41) | SSTR4MAPK1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL2255338 | 1.00 | SSTR4 (0.41) | SSTR4MAPK1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL28570518 | 0.86 | SSTR4 (0.33) | SSTR4MAPK1 | |
| SCHEMBL409182 | 0.80 | CHRNB2 (0.42) | MAPK1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL15170766 | 0.80 | CHRNB2 (0.40) | SSTR4MAPK1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL25225240 | 0.78 | CHRNB2 (0.41) | MAPK1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL27893276 | 0.78 | CHRNB2 (0.41) | MAPK1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL2281859 | 0.78 | CHRNB2 (0.41) | MAPK1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Iodide SCHEMBL1484659 | 0.77 | CHRNB2 (0.39) | MAPK1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL4303860 | 0.76 | MAPK1 (0.35) | SSTR4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234978-B1 | CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 | ASTRAZENECA AB (SE) | 2015-02-25 | — | — | EP | disclosed |
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-7994179-B2 | Carbamoyl compounds as DGAT1 inhibitors 190 | ASTRAZENECA AB (SE) | 2011-08-09 | — | — | US | disclosed |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | DGAT1, DGAT2, SOAT1 | SSTR4 1518/4885MAPK1 632/4885CHRNB2 3520/4885 |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | DGAT1, DGAT2, SOAT1 | SSTR4 1491/4885MAPK1 643/4885CHRNB2 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.